Peter Van Buskirk, CEO
Mr. Van Buskirk has broad experience in building technology-based businesses, including engineering management, operations, business development and IP licensing. He founded Sonata LLC, a distributor of ultra-high purity materials for LED and III-V semiconductor manufacturing. Mr. Van Buskirk began his career with Perkin-Elmer, managing an optical coating engineering group. In 1990 he joined ATMI, a start-up company in semiconductor materials. He was ATMI’s technical lead in a DARPA funded DRAM Consortium, which included IBM, Micron and Texas Instruments and formed the foundation for technology transfer to T.I. Subsequently he was Program Manager of Emosyn’s smart card alliance with Swatch. In 2000 Emosyn ramped up production of an innovative smartcard IC (SIM), using TSMC as their foundry partner; there are now over 6 billion fielded units. Mr. Van Buskirk has a B.A in History and B.S. in Physics, and holds 43 U.S. patents.
|
Jeff Roeder, CTO
Dr. Roeder brings 30 years of industrial R&D experience to Sonata Scientific, together with a passion for creating technologies that have a positive impact on people's lives. A strong advocate for collaborative development, he believes that diverse teams have an out sized potential to innovate. Prior to Sonata Scientific, he was a Managing Partner and Director of Products and Technology at Sonata, playing a significant role in building Sonata’s high volume chemical business and Sonata Scientific’s technical infrastructure. Previous roles include Director of R&D at ATMI, Inc. (now Entegris, Inc.) and Staff Engineer at IBM’s Semiconductor Research and Development Center. A co-inventor on over 90 U.S. Patents, Dr. Roeder has had numerous commercial deployments of technology throughout his career. He holds a Ph.D. and M.S. in Materials Science and Engineering and a B.S. in Metallurgy and Materials Engineering, all from Lehigh University.
|
Gene Banucci, Ph.D.
Founder, ATMI, Inc.
|
Gene Banucci founded ATMI, Inc. and served as CEO and/or Chairman/Director from 1986 to 2014. He, along with the founding team of scientists, had a vision of creating a preeminent semiconductor materials company. The company went public in 1993 with only $7 million in revenues, and grew to over $400 million annual revenues through an aggressive technology development and M&A strategy. In mid-2014, the Company was acquired by Entegris Corporation for approximately $1.2B. Prior to starting ATMI, Gene served as Vice President for American Cyanamid’s Chemical Research Division and was with General Electric Company in a variety of management positions at the Corporate R&D Center and GE Plastics.
Gene has served as a member of the Board of the Program on Innovation and Technology of the National Academy of Sciences, as a member of the Board of Trustees of Beloit College, and Director of over a dozen organizations, primarily leading cutting edge technology corporations. Presently he is Lead Director of Clean Harbors, a $3B environmental services company, and is Director and Governance Chair for Cognex Corporation. He received his PhD in Organic Chemistry from Wayne State University. Gene was awarded the Connecticut Medal of Technology in October of 2006 and was inducted into the Connecticut Academy of Sciences in 2007. |
Javad Parvizi, M.D., F.R.C.SJames Edward Professor of Orthopedic Surgery
|
Dr. Javad Parvizi is a board certified orthopaedic surgeon. He has been at the Rothman Institute since 2003. He has performed over 1000 femoroacetabular osteoplasty procedures, 300 pelvic and femoral osteotomies, and over 5000 hip replacements in young adults. He completed medical school at the University of Sheffield (UK), obtained a Masters degree in molecular biology from the Mayo Clinic, and subsequently performed a residency in orthopedic surgery there. This was followed by a fellowship in the management of hip disorders in young adults at the Inselspital, Berne (Switzerland).
Dr. Parvizi’s personal area of interest in research and clinical practice includes prevention and diagnosis of joint infection, joint preservation in adults, and prevention of thromboembolism following orthopedic procedures. He has published over 700 scientific articles and has written 18 text books in related subjects including books on THE HIP and on THE KNEE. He has received awards from societies and has received funding for his research from the National Institute of Health, Department of Defense, Orthopedic Research and Education Foundation, Musculoskeletal Transplant Foundation, Arthritis Foundation and numerous other funding bodies. He has served as the president of Musculoskeletal Infection Society (2013), Eastern Orthopedic Association (2018) and holds position the board of numerous organizations and societies. |
Thomas J. Webster, Ph.D.
Arthur W. Zafiropoulo Professor and Chairman
|
Thomas J. Webster’s (H index: 90) degrees are in chemical engineering from the University of Pittsburgh (B.S., 1995) and in biomedical engineering from Rensselaer Polytechnic Institute (M.S., 1997; Ph.D., 2000). Professor Webster has graduated/supervised over 219 graduate students and his lab group has generated over 700 peer reviewed articles, 13 textbooks, 68 book chapters, 276 invited presentations, 867 conference presentations, and 42 provisional or full patents. He has formed 12 companies who collectively have over 21 FDA approved medical products currently helping the lives of thousands. He is the founding editor-in-chief of the International Journal of Nanomedicine (pioneering the open-access format) and an associate editor of Nanomedicine: NBM.
Professor Webster is a fellow of over 8 societies and currently directs 3 international centers in biomaterials. He has appeared on BBC, NBC, ABC, Fox News, the Weather Channel, the Discovery Channel, and the recent special ‘Year Million’ TV series on National Geographic talking about the future of medicine and science. |
© 2019 Sonata Scientific
|
Website by Steers Studios
|